The resurgence of phenotypic screening in drug discovery and development

Expert Opinion on Drug Discovery

Volumn 11, Issue 2, 2016, Pages 121-125

  Wagner, Bridget K ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE;

CAENORHABDITIS ELEGANS; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MECHANISM; DRUG SCREENING; GENE EXPRESSION; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PHENOTYPE; PHENOTYPIC SCREENING; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SCREENING; ZEBRA FISH; ANIMAL; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; PHENOTYPE;

EID: 84957432261     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2016.1122589     Document Type: Review

References (28)

1. Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today. 2013; 18: 1067-1073.
2. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011; 10: 507-519.
3. Moffatt JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery-past, present and future. Nat Rev Drug Discov. 2014; 13: 588-602.
4. Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007; 6: 29-40.
5. Guiguemde WA, Shelat AA, Garcia-Bustos JF, et al. Global phenotypic screening for antimalarials. Chem Biol. 2012; 19: 116-129.
6. Vincent F, Loria P, Pregel M, et al. Developing predictive assays: the phenotypic screening "rule of 3". Sci Transl Med. 2015; 7: 293ps15.
7. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011; 108: 18843-18848.
8. Rottmann M, McNamara C, Yeung BK, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010; 329: 1175-1180.
9. Swinney DC. The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines. J Biomol Screen. 2013; 18: 1186-1192.
10. Schreiber SL, Kotz JD, Li M, et al. Advancing biological understanding and therapeutics discovery with small-molecule probes. Cell. 2015; 161: 1252-1265.
11. Gregori-Puigjané E, Setola V, Hert J, et al. Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci USA. 2012; 109: 11178-11183.
12. Schirle M, Jenkins JL. Identifying compound efficacy targets in phenotypic drug discovery. Drug Discov Today. 2015. DOI: 10.1016/j.drudis.2015.08.001.
13. Schenone M, Dančík V, Wagner BK, et al. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol. 2013; 9: 232-240.
14. Kronkë J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014; 343: 301-305.
15. Savitski MM, Reinhard FB, Franken H, et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 2014; 346: 1255784.
16. Hughes TR, Marton MJ, Jones AR, et al. Functional discovery via a compendium of expression profiles. Cell. 2000; 102: 109-126.
17. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006; 313: 1929-1935.
18. Gustafsdottir SM, Ljosa V, Sokolnicki KL, et al. Mutliplex cytological profiling assay to measure diverse cellular states. PLoS One. 2013; 8: e80999.
19. Petrone PM, Simms B, Nigsch F, et al. Rethinking molecular similarity: comparing compounds on the basis of biological activity. ACS Chem Biol. 2012; 7: 1399-1409.
20. Dančík V, Carrel H, Bodycombe N, et al. Connecting small molecules with similar assay performance profiles leads to new biological hypotheses. J Biomol Screen. 2014; 19: 771-781.
21. Lukens AK, Heidebrecht RW Jr, Mulrooney C, et al. Diversity-oriented synthesis probe targets plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors. J Infect Dis. 2015; 211: 1097-1103.
22. Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014; 343: 84-87.
23. Johannessen CM, Clemons PA, Wagner BK. Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery. Trends Genet. 2015; 31: 16-23.
24. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013; 12: 581-594.
25. Khurana V, Tardiff DF, Chung CY, et al. Toward stem cell-based phenotypic screens for neurodegenerative diseases. Nat Rev Neurol. 2015; 11: 339-350.
26. Prior M, Chiruta C, Currais A, et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 2014; 5: 503-513.
27. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov. 2015; 14: 248-260.
28. Walpita D, Wagner BK. Evaluation of compounds in primary human islet cell culture. Curr Protoc Chem Biol. 2014; 6: 157-168.